Skip to Main

2022 Publications

  1. Chen R, Wang J, Gradinaru I, Vu HS, Geboers S, Naidoo J, Ready JM, Williams NS, DeBerardinis RJ, Ross EM, Collins JJ 3rd. A male-derived nonribosomal peptide pheromone controls female schistosome development. Cell. 2022 Apr 28;185(9):1506-1520 PMCID: PMC9058237.
  2. Sharma A, Elias R, Christie A, Williams NS, Pedrosa I, Bjarnason GA, Brugarolas J. Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma. Kidney Cancer. 2022;6(1):69-79.  PMCID: PMC9894028.
  3. Dong X, Liang Q, Pan YZ, Wang X, Kuo YC, Chiang WC, Zhang X, Williams NS, Rizo J, Levine B, De Brabander JK. Novel Bcl-2 Inhibitors Selectively Disrupt the Autophagy-Specific Bcl-2-Beclin 1 Protein-Protein Interaction. ACS Med Chem Lett. 2022 Sep 8;13(9):1510-1516.  PMCID: PMC9465831.
  4. Udden SN, Wang Q, Kumar S, Malladi VS, Wu SY, Wei S, Posner BA, Geboers S, Williams NS, Liu YL, Sharma JK, Mani RS, Malladi S, Parra K, Hofstad M, Raj GV, Larios JM, Jagsi R, Wicha MS, Park BH, Gupta GP, Chinnaiyan AM, Chiang CM, Alluri PG. Targeting ESR1 mutation-Induced transcriptional addiction in breast cancer with BET inhibition.  JCI Insight. 2022 Sep 8;7(17).  PMCID: PMC9536271.
  5. Jiang L, Liu Y, Su X, Wang J, Zhao Y, Tumbath S, Kilgore JA, Williams NS, Chen Y, Wang X, Mendonca MS, Lu T, Fu YX, Huang X. KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway. Front Oncol. 2022;12:976292. PMCID: PMC9530825.
  6. Jain MK, De Lemos JA, McGuire DK, Ayers C, Eitson JL, Sanchez CL, Kamel D, Meisner JA, Thomas EV, Hegde AA, Mocherla S, Strebe JK, Li X, Williams NS, Xing C, Ahmed MS, Wang P, Sadek HA, Schoggins JW. Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial. Front Pharmacol. 2022;13: 1020123.  PMCID: PMC9561237.
  7. Pontikos MA, Leija C, Zhao Z, Wang X, Kilgore J, Tornesi B, Adenmatten N, Phillips MA, Williams NS. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 2022 Oct;204: 115237.  PMCID: PMC9547971.
  8. Hu B, Toda K, Wang X, Antczak MI, Smith J, Geboers S, Nishikawa G, Li H, Dawson D, Fink S, Desai AB, Williams NS, Markowitz SD, Ready JM. Orally Bioavailable Quinoxaline Inhibitors of 15-Prostaglandin Dehydrogenase (15-PGDH) Promote Tissue Repair and Regeneration. J Med Chem. 2022 Nov 24;65(22):15327-15343.  PMCID: PMC9885488.
Back-to top